A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study

BACKGROUND: Although B cell depletion with rituximab (RTX) is an effective treatment strategy in rheumatoid arthritis (RA), one third of patients do not achieve remission or low disease activity (LDA). Thus, identifying patients who will benefit from RTX is highly desirable. In the present study we...

Descripción completa

Detalles Bibliográficos
Autores principales: Stradner, Martin H., Dejaco, Christian, Brickmann, Kerstin, Graninger, Winfried B., Brezinschek, Hans Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997751/
https://www.ncbi.nlm.nih.gov/pubmed/27558631
http://dx.doi.org/10.1186/s13075-016-1091-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997751/
https://www.ncbi.nlm.nih.gov/pubmed/27558631
http://dx.doi.org/10.1186/s13075-016-1091-1

Ejemplares similares